Correlations Between the Genetic Variations in the COL1A1, COL5A1, COL12A1, and β-fibrinogen Genes and Anterior Cruciate Ligament Injury in Chinese Patients

Daohong Zhao, MD*; Qi Zhang, MM†; Qingnan Lu, MM†; Chen Hong, MM†; Tinghu Luo, MM†; Qihui Duan, MM†; Songhua Shu, BS†; Jiang Lv, BS†; Wenchuan Zhao, MM†

*Orthopaedic Department, The Second Affiliated Hospital of Kun Ming Medical University, Yunnan Province, China; †Sports Medicine and Joint Surgery, First People’s Hospital of Kunming, Yunnan Province, China

Context: A variety of factors have been linked to the occurrence of anterior cruciate ligament injury (ACLI), including sex, familial factors, and genetic variations.

Objective: To find the genetic loci associated with ACLI and explore the genetic mechanism of ACLI in order to provide a genetic basis for the diagnosis, prognosis, and treatment of patients with ACLI.

Design: Cross-sectional study.

Setting: Hospital.

Patients or Other Participants: Data from 101 Chinese Yunnan Han patients with ACLI and 110 Yunnan Han individuals without ACLI (control group) were collected.

Main Outcome Measure(s): The single nucleotide polymorphisms of COL1A1 rs1800012, COL5A1 rs12722 and rs13946, COL12A1 rs970547 and rs240736 and the rs1800787, rs1800788, rs1800790, rs1800791, and rs2227389 in the β-fibrinogen (β-fib) promoter region were analyzed using restriction fragment length polymorphism and DNA sequencing detection, and their genetic associations with ACLI were assessed.

Results: Single nucleotide polymorphisms of COL1A1 rs1800012, COL5A1 rs12722 and rs13946, and the rs1800789 and rs1800791 in the β-fib promoter region showed no difference between patients with ACLI and control participants, but the changes of COL12A1 rs970547 and rs240736 and the rs1800787, rs1800788, rs1800790, and rs2227389 genotypes in the β-fib promoter region were associated with ACLI. Furthermore, the rs970547 allele and genotype frequencies in male ACLI patients were different from the control group (P < .05); the frequencies of the rs970547 A and G alleles in the patients were 71.9% and 28.1%, respectively, and in the control group were 58.8% and 41.2%, respectively. The frequencies of AA, AG, and GG genotypes in the patients were 49.3%, 45.2%, and 5.5%, respectively, and in the control group were 27.5%, 62.7%, and 9.8%, respectively, suggesting that male carriers of rs970547 A and rs970547 AA were at high risk of ACLI.

Conclusions: Males with the rs970547 A allele and rs970547 AA genotype of COL12A1 may be at high risk for ACLI. Low rs1800787 TT and high rs1800788 CT, rs1800790 AG, and rs2227389 CT frequencies as well as high TGA* of rs1800789, rs1800791, and rs2227389 in the β-fib promoter region may be genetic risk factors related to ACLI.

Key Words: polymorphisms, β-fib promoter, knee injury

Key Points

- Collagen susceptibility genes in Chinese Han participants with anterior cruciate ligament injury (ACLI) were different from those of other races.
- The rs970547 and rs240736 of COL12A1 gene were correlated with ACLI in Chinese males. Male individuals carrying the rs970547 A allele of the COL12A1 gene and the AA genotype might have an increased risk of ACLI.
- The promoter regions rs1800790, rs1800788, and rs1800787 of the β-fib gene and their haplotypes may be related to the occurrence of ACLI.

The anterior cruciate ligament (ACL) is an important stabilizing structure in the human knee joint. With the popularity and extensive development of national sports, ACL injury (ACLI) is a common injury. Although ACLI often results from a noncontact mechanism, the bending angle of the knee joint, the tension of the quadriceps muscle, and the ground reaction force on the leg during exercise are closely related to the increase in knee valgus moment. The important role of the ACL in the knee joint is that, when the injury occurs, the anterior hypermobility of the tibia causes instability of the knee joint, which in turn damages the articular cartilage and menisci and further accelerates the degenerative changes of the knee joint and osteoarthritis. The incidence of ACLI in the US population is about 1/3000, which is significantly higher than that of the general population.
incidence rate of ACLI for active athletes in China is 0.43%. However, in recent years, the number of ACLIs in nonathletes increased to a level that was significantly higher than that of professional athletes.

At present, our understanding of the pathogenesis of ACLI is not very clear. Many factors, including sex, family factors, and specific genetic variations have been shown to be related to ACLI. The incidence in women is reported to be higher than that of men. Further, the incidence of ACLI in first-degree relatives of ACLI patients is more than twice that of uninjured people, suggesting that genetic factors play a role in ACLI. Some collagen gene polymorphisms have been associated with ACLI. The COL1A1 gene encodes a protein chain in type 1 collagen, a major structural component of ligaments. Anterior cruciate ligament-injured patients were 4 times more likely to have a family member with a ligamentous injury of any kind compared with control individuals. Similarly, the CC genotype of a variant in the COL5A1 has been found in female patients with ACLI. The COL5A1 gene codes for a protein chain in type 5 collagen, found in ligaments and tendons. Third, these investigators found that the AA genotype of the COL12A1 Alu I polymorphism was overrepresented in female patients with ACLI. This gene encodes for protein chains in type 12 collagen, which is believed to regulate fibril diameter in ligaments. An association was reported between the chromosomal region 11q22 and the risk of ACLI. Several matrix metalloproteinase genes, including those that are physiological mediators of collagen cleavage and removal, are located on chromosome 11q22. Posthumus et al confirmed that the COL1A1 Sp1 binding site TT type was significantly less in ACLI patients in South Africa than in the control group, suggesting that this polymorphism may be a special genetic factor in the multivariate model of ACLI. It was speculated that the G-to-T substitution of the intron of the Sp1 binding site increased the affinity of the Sp1 transcription factor, thereby increasing the expression of the COL1A1 gene. Analysis of the COL5A1 gene polymorphism showed that the frequency of the COL5A1 BstUI restriction fragment length polymorphism (RFLP) CC genotype of females with ACLI was higher than that of the control. Female COL12A1 Alu I RFLP AA has also been associated with an increased risk for ACLI. In addition, polymorphisms of β-fibrinogen (β-fib) were involved in the rate-limiting steps of the formation of the β-chain and were closely related to elevation of the plasma fibrinogen level. Several studies have suggested that β-fib polymorphism was associated with an elevated plasma fibrinogen concentration and ischemic stroke. The correlation between these related gene polymorphisms and ACLI in the Chinese population has not been reported.

Our aim was to investigate the single nucleotide polymorphisms (SNPs) of the COL1A1, COL5A1, COL12A1, and β-fib gene promoter regions of ACLI patients in the Chinese population to identify their correlation with the pathogenesis of ACLI.

METHODS

General Information

The study involved 101 patients with ACLI (73 males and 28 females) and 110 healthy control participants without ACLI (69 males and 41 females). The average ages were 33.62 ± 11.18 years of the ACLI patients and 35.57 ± 12.78 years of the control participants. A total of 327 patients with signs and symptoms of knee injury underwent arthroscopic examination in our hospital; of these, 41 ACLI patients with left-sided injuries and 60 with right-sided injuries were selected for this study. Control individuals with normal knees were randomly selected from the general population, and magnetic resonance imaging confirmed they had no organic knee-joint injury such as ACLI, meniscus tear, or fracture. Control recruits were matched by age and sex to the ACLI participants. Demographic information is shown in Table 1. The trial was approved by our hospital and the Clinical Research Ethics Committee of First People’s Hospital of Kunming University. All participants signed the consent form. Inclusion criteria were (1) clinical physical examination indicated knee instability; (2) magnetic resonance imaging examination confirmed fiber discontinuity by coronal and axial imaging, the empty notch sign on coronal imaging, thickening and edema of the ACL (increased signal intensity on T2 or intermediate-weighted sequences), the fibers being completely absorbed or the residual ACL stump adherent to the synovial envelope covering the posterior cruciate ligament; (3) arthroscopic examination of the ACLI; (4) nonmechanical damage. Exclusion criteria were (1) ACLI combined with ligament injury in another part of the knee joint; (2) patients with previous knee disease such as rheumatism or rheumatoid arthritis, septic arthritis, or knee-joint tuberculosis; or (3) patients with previous knee surgery.

Sample Collection and DNA Extraction

A total of 5 mL of peripheral venous blood of all participants was collected and anticoagulated with ethylene diamine tetra-acetic acid (Tianjin Flourish Chemical Co, Ltd, Hebei District, Tian Jin, China). Genomic DNA was extracted from samples using the AxyPrep Blood Genomic DNA Mini Kit (Shanghai Haorui Biotechnology Co, Ltd, Shanghai, China).

Detection of Polymorphic Loci

The SNPs detected were COL1A1 gene intron rs1800012, COL5A1 gene 3’-UTR rs12722 and rs13946, COL12A1

| Table 1. General Information of Patients With Anterior Cruciate Ligament Injuries and Control Participants |
|---------------------------------|-----------------|-----------------|
| Characteristic | Anterior Cruciate Ligament Injury (n = 101) | Control Individuals (n = 110) |
| Sex | Male | 73 | 69 |
| | Female | 28 | 41 |
| Side of anterior cruciate ligament injury | Left | 41 | 0 |
| | Right | 60 | 0 |
| Mean ± SD | Age, y | 33.62 ± 11.18 | 35.57 ± 12.78 |
| | Height, cm | 167.51 ± 6.46 | 165.43 ± 7.82 |
| | Weight, kg | 64.39 ± 8.07 | 63.57 ± 9.03 |
gene exons rs970547 and rs240736 and the rs1800787, rs1800788, rs1800789, rs1800790, rs1800791, and rs2227389 in the β-fib gene promoter region.

Polymerase Chain Reaction Restriction Fragment Length Polymorphism

Polymerase chain reaction (PCR) mixtures were prepared according to the instructions supplied with the AmpliTaq Gold kit (Applied Biosystems, Foster City, CA), which contained 200 μM of deoxynucleoside triphosphate, 2.5 μL of 10 × reaction buffer (100 mM Tris-HCl at pH 8.3, 500 mM KCl), 1.5 mM MgCl₂, a 0.1 μM concentration of the primers with 2.5 U of Taq DNA polymerase, and 5 ng of template DNA. The volume of this mix was adjusted to 25 μL with sterile water. The PCR reaction conditions were as follows: an initial denaturation at 94°C for 3 minutes, followed by 30 cycles of denaturation at 94°C for 30 seconds, annealing at 59°C for 30 seconds, extension at 72°C for 120 seconds, and a final extension step at 72°C for 10 minutes. The COL5A1 (rs12722, rs13946) and COL12A1 (rs970547, rs240736) amplicons were subsequently digested using BstUI (NEB), DpnII (NEB), AluI (NEB), and BsrI (NEB) for RFLP analysis. Primers used for PCR RFLP in this study are shown in Table 2.

Single Nucleotide Polymorphism Sequencing

The amplicons of COL1A1 (rs1800012) and COL12A1 (rs970547, rs240736) and the rs1800787, rs1800788, rs1800789, rs1800790, rs1800791, and rs2227389 of the β-fib gene promoter region were sequenced to detect SNPs (Table 2). (Primers were provided by Shanghai Bioengineering Co, Ltd, Shanghai, China.) The haplotypes were generated using the 2 SNPs of rs12722 and rs13946 and 3 SNPs of rs1800790, rs1800791, and rs2227389 in the ACLI patients and control individuals.

Genetic Polymorphisms

The 351 and 316 bp DNA fragments generated by rs12722 BstUI RFLP suggested that they were homozygous for TT, and the 316-, 271-, and 80-bp fragments suggested a CC homozygote. The 418-, 194-, 40-, and 15-bp fragments produced by rs13946 DpnII RFLP were homozygous for TT, and the 612-, 40-, and 15-bp fragments were homozygous for CC. The 460-, 139-, and 16-bp fragments produced by rs970547 AluI RFLP were defined as AA homozygotes, and the 599- and 16-bp fragments were homozygous for GG. The 480-bp fragment produced by rs240736 BsrI RFLP digestion was TT homozygous, and the 322- and 158-bp fragments represented CC homozygotes.

Statistical Analysis

The χ² test was used to analyze the frequency of allele, genotype, and haplotype distributions. Hardy-Weinberg equilibrium testing for genotypes was performed using the online calculator (http://www.oege.org/software/hwe-mr-calc.shtml). Haplotype analysis was carried out using http://analysis2.bio-x.cn/myAnalysis.php.¹⁴ Statistical significance was set at P < .05.

RESULTS

Clinical Results

Magnetic resonance imaging confirmed 101 patients with ACLI and 110 control participants without ACLI. Age, sex, height, and weight did not differ between the groups (P > .05; Table 1).

Allele and Genotype Frequencies

As shown in Table 3, the allele frequency was not statistically different between the patients and the control individuals (P > .05). The genotype frequency distribution was consistent with the Hardy-Weinberg equilibrium, except for rs1800791 (P < .01). In comparing genotype frequencies, we found that rs1800787 TT was less frequent in the patients than in the control group (P < .05). In contrast, rs1800788 CT, rs1800790 AG, and rs2227389 CT were higher in the patients than in the control group (P < .05). Other genotypes, such as rs1800012, rs12722, rs13946, rs970547, rs240736, and rs1800789, showed no difference between the groups (P > .05). We suggest that the changes of the rs1800787, rs1800788, rs1800790, and rs2227389 genotypes are associated with ACLI.
Table 3. Comparison of Allele and Genotype Frequency Between Patients With Anterior Cruciate Ligament Injury (n = 101) and Control Individuals (n = 110)

| Gene      | Single Nucleotide Polymorphisms | Allelic Count, No. (%) | Allelic P Value | Genotype Count | Genotypic P Value | Hardy-Weinberg Equilibrium P Value |
|-----------|---------------------------------|------------------------|----------------|----------------|------------------|-----------------------------------|
| COL1A1    | rs1800012                        | G T                    | >.05           | GG 2 1         | >.05 >.05        |
| Patients  | 200 (99)                         | 2 (1)                 | .05            | 98 2 1         | >.05 >.05        |
| Control individuals | 220 (100)            | 0 (0)                 |                | 107 2 1        | >.05 >.05        |
| COL5A1    | rs12722                          | C T                    | >.05           | CC 37 8        | >.05 >.05        |
| Patients  | 152 (75)                         | 50 (25)               | >.05           | 56 37 8        | >.05 >.05        |
| Control individuals | 172 (78.2)        | 48 (21.8)             | >.05          | 68 36 6        | >.05 >.05        |
| COL5A1    | rs13946                          | C T                    | >.05           | CC 42 11       | >.05 >.05        |
| Patients  | 79 (39.9)                        | 123 (60.1)            | >.05           | 17 45 39       | >.05 >.05        |
| Control individuals | 92 (42)              | 128 (58)              | >.05          | 19 59 32       | >.05 >.05        |
| COL12A1   | rs970547                         | A G                    | >.05           | AA 42 11       | >.05 >.05        |
| Patients  | 141 (69.3)                       | 61 (30.7)             | >.05           | 48 42 11       | >.05 >.05        |
| Control individuals | 141 (64)          | 79 (36)               | >.05          | 39 59 16       | >.05 >.05        |
| COL12A1   | rs240736                         | C T                    | >.05           | CC 37 62       | >.05 >.05        |
| Patients  | 36 (17.8)                        | 166 (82.2)            | >.05           | 2 37 62        | >.05 >.05        |
| Control individuals | 26 (11.8)         | 194 (88.2)            | >.05          | 1 34 75        | >.05 >.05        |
| β-fibrinogen | rs1800787                     | C T                    | >.05           | CC 37 62       | >.05 >.05        |
| Patients  | 162 (80)                         | 40 (20)               | >.05           | 61 38 2        | <.05 >.05        |
| Control individuals | 161 (73.2)        | 59 (26.8)             | >.05          | 64 35 11       | <.05 >.05        |
| β-fibrinogen | rs1800788                     | C T                    | >.05           | CC 37 62       | >.05 >.05        |
| Patients  | 75 (34)                          | 145 (66)              | >.05           | 15 40 55       | >.05 >.05        |
| Control individuals | 85 (42)              | 117 (58)              | >.05          | 17 53 31       | <.05 >.05        |
| β-fibrinogen | rs1800789                     | A G                    | >.05           | AA 39 61       | <.05 >.05        |
| Patients  | 47 (23)                          | 155 (77)              | >.05           | 9 39 61        | <.05 >.05        |
| Control individuals | 46 (21)            | 174 (79)              | >.05          | 7 39 64        | <.05 >.05        |
| β-fibrinogen | rs1800790                     | A G                    | >.05           | AA 39 61       | <.05 >.05        |
| Patients  | 38 (19)                          | 164 (81)              | >.05           | 9 39 61        | <.05 >.05        |
| Control individuals | 40 (18)            | 180 (82)              | >.05          | 6 26 78        | <.05 >.05        |
| β-fibrinogen | rs1800791                     | A G                    | >.05           | AA A/G 90      | <.05 <.01        |
| Patients  | 12 (6)                           | 190 (94)              | >.05           | 4 7 90         | <.05 <.01        |
| Control individuals | 9 (4)              | 211 (96)              | >.05          | 9 9 99         | <.05 <.01        |
| β-fibrinogen | rs2227389                     | C T                    | >.05           | CC 37 62       | >.05 >.05        |
| Patients  | 166 (82)                         | 36 (18)               | >.05           | 62 38 1        | >.05 <.05        |
| Control individuals | 183 (83)            | 37 (17)               | >.05          | 74 29 7        | >.05 <.05        |
Linkage Disequilibrium Between SNPs

The linkage disequilibrium (LD) analysis of the SNPs of the collagen genes showed that rs12722 and rs13946 LD were higher in patients with ACLI than in control participants. The remaining sites rs1800012, rs970547, and rs240736 were less linked between the patients and control individuals (Figure 1). The \( \beta \)-fibrinogen gene promoter regions rs1800790, rs1800791, and rs2227389 had higher LD in the ACLI patients (Figure 2). The remaining regions rs1800787, rs1800788, and rs1800789 in the patient group were not associated with those in the control group.

Stratification Analysis

Further analysis showed that the frequencies of the rs970547 A and G alleles in males were different between the patient group and the control group \((P = .019)\). The frequencies of A and G in the patients were 71.9% and 28.1%, respectively, and in the control participants were 58.8% and 41.2%, respectively. The frequencies of the rs970547 AA, AG, and GG genotypes in the patient group were 49.3%, 45.2%, and 5.5%, respectively, and in the control group were 27.5%, 62.7%, and 9.8%, respectively.

Haplotype Analysis

According to the results of the LD analysis, the rs12722 and rs13946 haplotypes (Table 5) and rs1800790, rs1800791, and rs2227389 haplotypes (Table 6) were constructed. No statistical differences in rs12722 and rs13946 haplotype distributions were present between the groups (Table 5; \( P > .05 \)). However, differences were noted between the haplotypes of TGG*, CGA*, and TGA* of rs1800790, rs1800791, and rs2227389. The detection rates of haplotypes TCG* and CGA* of rs1800790, rs1800791, and rs2227389 in patients were significantly lower than in control participants (Table 6; \( P < .001 \)), whereas haplotype TGA* was higher in the patients than in the control group (Table 6; \( P = .0228 \)), suggesting that this combination of SNPs was likely to be the genetic background of Chinese patients with ACLI.

DISCUSSION

Collagen Gene Variants and ACLI

At present, the genetic factors of ACLI are mostly focused on the polymorphism of collagen genes in different regions. In the Caucasian population of South Africa, Khoschnau et al.\(^{19} \) observed that the polymorphism of the \( COL1A1 \) Sp1 binding site was associated with ACLI in Caucasians. In 2009, Posthumus et al. confirmed that the TT type of the Sp1 binding site was significantly less in South African patients with ACLI.\(^{11} \) Population genetics showed that the frequency of the rs1800012 T allele was 20% and of the G allele was 80% in European populations. In the American population, T was 16% and G was 84%. In the Asian population, T was only 1% and G was 99%.\(^{12} \) We did not observe an association between ACLI and the Sp1 binding sites in the Yunnan Han population, indicating that the polymorphism of rs1800012 in the Chinese population was insufficient and that it was not a site related to ACLI.

Mokone et al.\(^{20} \) studied 111 cases of Achilles tendon injury in the Caucasian population of South Africa, 39 patients with spontaneous tendon ruptures, and 129 asymptomatic sports enthusiasts and found that only the rs12722-BstUI polymorphism of \( COL5A1 \) gene was associated with chronic Achilles tendinitis. Among 85 Australian Caucasian patients with Achilles tendon injury, the rs12722-
BstUI and rs13946-DpnII polymorphisms were associated with Achilles tendon injury. The frequency of the rs12722 BstUI CC genotype in female patients with ACLI was higher than in the control group. This investigation demonstrated that the frequencies of rs12722 C and T alleles in the Yunnan Han population were consistent with the allelic frequency distribution previously reported in Asian populations, but they were not genetic risk factors in the Chinese population. Additionally, the findings for the COL12A1 gene were different. Posthumus et al reported that, in the Caucasian population, the risk of ACLI was increased in females with rs970547 AluI RFLP AA. However, September et al did not find that the COL12A1 gene was associated with Achilles tendon injury. We observed no difference in the rs970547 A and rs2407389 C and T alleles compared with the patient group. Further analysis showed that male patients with ACLI carried more rs970547 A alleles and AA genotypes, but statistical differences were present in female patients.

**β-fibrinogen** Gene Variants and Anterior Cruciate Ligament Injury

At the time of ACLI and after surgery, fibrinogen levels often increase significantly. The β-fib gene determines the synthesis of the fibrin β polypeptide chain, which in turn affects most of the changes in plasma fibrinogen levels. Deficient fibrinogen in anterior cruciate ligament wound sites has been demonstrated. In this study, rs1800787 TT was lower in the patient group than in the control group. Also, rs1800788 CT, rs1800790 AG, and rs2227389 CT were higher in the patients than in the control participants, suggesting that changes in rs1800787, rs1800788, rs1800790, and rs2227389 genotypes were associated with ACLI. Here, rs1800787 TT seemed to confer protection against ACLI. The detection rate of haplotypes of TGG*, CGA*, and TGA* of rs1800787, rs1800790, and rs2227389 in the patients with ACLI was lower than that in the control group, whereas the TGA* was higher in the patients, indicating that this combination of changes is likely to be the genetic background of the ACLI pathogenesis in Chinese individuals.

**CONCLUSIONS**

The COL1A1 gene Sp1 binding site rs1800012, as well as the rs12722 and rs13946 sites, were not susceptible sites for ACLI in the Chinese Han population. The COL12A1 gene rs970547 and rs2407389 had a correlation with ACLI in Chinese men. Male individuals carrying the COL12A1 gene rs970547 A allele and AA genotype may have an increased risk of ACLI. The sites of the promoter region of the β-fib gene rs1800788 CT, rs1800790 AG, and rs2227389 CT and haplotypes of TGG*, CGA*, and TGA* of rs1800790, rs1800791, and rs2227389 may be associated with the genetic background of ACLI. The rs1800787 TT polymorphism may offer genetic protection against ACLI among Chinese individuals.

**REFERENCES**

1. Slauterbeck JR, Kousa P, Clifton BC, et al. Geographic mapping of meniscus and cartilage lesions associated with anterior cruciate ligament injuries. *J Bone Joint Surg Am*. 2009;91(9):2094–2103.
2. Lohmander LS, Englund PM, Dahl LL, Roos EM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. *Am J Sports Med*. 2007;35(10):1756–1769.
3. Griffin LY, Agel J, Albohm MJ, et al. Noncontact anterior cruciate ligament injuries: risk factors and prevention strategies. *J Am Acad Orthop Surg*. 2000;8(3):141–150.
4. Ao YF, Tian DX, Cui GQ, Hu YL. Epidemiological study on athletes’ anterior cruciate ligament injury. *SPRT Science*. 2000;20:47–48.
5. Wang J, Ao YF. Clinical epidemiological study of anterior cruciate ligament injury. *Chin J Sports Med*. 2001;20:380–382.
6. John R, Dhillon MS, Sharma S, Prabhakar S, Bhandari M. Is there a genetic predisposition to anterior cruciate ligament tear? A systematic review. *Am J Sports Med*. 2016;44(12):3262–3269.
7. John R, Prabhakar S, Dhillon MS, Anand A, Minhas G. Association of ACL tears and single nucleotide polymorphisms in the collagen 12 A1 gene in the Indian population: a preliminary case-control study. *Muscle Ligaments Tendons J*. 2016;6(2):253–257.
8. Smith IK. On bended knee: more girls are tearing ligaments in their knees. Here’s what they can do to prevent it. *Time*. 2000;156(20):120.
9. Griffin LY, Albohm MH, Arendt EA, et al. Understanding and preventing noncontact anterior cruciate ligament injuries: a review.

---

**Table 5. Haplotypes of rs12722 and rs13946 in Patients With Anterior Cruciate Ligament Injury and Control Individuals**

| Haplotype | Patients, No. (%) | Control Individuals, No. (%) | \( \chi^2 \) | \( P \) Value | Odds Ratio (95% Confidence Interval) |
|-----------|-------------------|-------------------------------|------------|--------------|-------------------------------------|
| CC*       | 75.38 (0.373)     | 89.00 (0.436)                 | 1.512      | .2189        | 0.779 (0.523, 1.160)                |
| CT*       | 74.62 (0.369)     | 71.00 (0.348)                 | 0.260      | .6105        | 1.111 (0.740, 1.668)                |
| TC        | 1.62 (0.008)      | 0.00 (0.000)                  |            |              |                                     |
| TT*       | 50.38 (0.249)     | 44.00 (0.216)                 | 0.722      | .3955        | 1.221 (0.770, 1.938)                |

**Table 6. Haplotypes of rs1800790, rs1800791, and rs2227389 in Patients With Anterior Cruciate Ligament Injury and Control Individuals**

| Haplotype | Patients, No. (%) | Control Individuals, No. (%) | \( \chi^2 \) | \( P \) Value | Odds Ratio (95% Confidence Interval) |
|-----------|-------------------|-------------------------------|------------|--------------|-------------------------------------|
| CAA       | 0.00 (0.000)      | 0.38 (0.001)                  |            |              |                                     |
| CAG       | 11.00 (0.053)     | 8.62 (0.032)                  | 1.226      | .2682        |                                     |
| CGA       | 0.00 (0.000)      | 13.55 (0.051)                 | 10.920     | .0001        | 1.665 (0.670, 4.139)                |
| CGG       | 157.00 (0.755)    | 194.45 (0.731)                | 0.315      | .5744        |                                     |
| TGA       | 40.00 (0.192)     | 31.07 (0.117)                 | 5.189      | .0228        | 1.127 (0.743, 1.709)                |
| TGG       | 0.00 (0.000)      | 17.93 (0.067)                 | 14.592     | .0001        | 1.797 (1.080, 2.989)                |
| TAA       | 0.00 (0.000)      | 0.00 (0.000)                  |            |              |                                     |
of the Hunt Valley II meeting, January 2005. Am J Sports Med. 2006;34(9):1512–1532.

10. Flynn RK, Pedersen CL, Birmingham TB, Kirkley A, Jackowski D, Fowler PJ. The familial predisposition toward tearing the anterior cruciate ligament: a case control study. Am J Sports Med. 2005;33(1):23–28.

11. Posthumus M, September AV, Keegan M, et al. Genetic risk factors for anterior cruciate ligament ruptures: COL1A1 gene variant. Br J Sports Med. 2009;43(5):352–356.

12. Posthumus M, September AV, O’Cuinneagain D, van der Merwe W, Schwellnus MP, Collins M. The COL5A1 gene is associated with increased risk of anterior cruciate ligament ruptures in female participants. Am J Sports Med. 2009;37(11):2234–2240.

13. Posthumus M, September AV, O’Cuinneagain D, van der Merwe M, Schwellnus MP, Collins M. The association between the COL12A1 gene and anterior cruciate ligament ruptures. Br J Sports Med. 2010;44(16):1160–1165.

14. Posthumus M, Collins M, van der Merwe L, et al. Matrix metalloproteinase genes on chromosome 11q22 and the risk of anterior cruciate ligament (ACL) rupture. Scand J Med Sci Sports. 2012;22(4):523–533.

15. Mann V, Hobson EE, Li B, et al. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest. 2001;107(7):899–907.

16. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97–98.

17. Kumar A, Misra S, Kumar P, Sagar R, Prasad K. Association between beta-fibrinogen C148T gene polymorphism and risk of ischemic stroke in a North Indian population: a case-control study. Pulse (Basel). 2017;44(4):165–171.

18. Liu Y, Pan J, Wang S, Li X, Huang Y. beta-fibrinogen gene -455A/G polymorphism and plasma fibrinogen level in Chinese stroke patients. Chin Med J (Engl). 2002;115(2):214–216.

19. Khoschnau S, Melhus H, Jacobson A, et al. Type I collagen alpha1 Sp1 polymorphism and the risk of cruciate ligament ruptures or shoulder dislocations. Am J Sports Med. 2008;36(12):2432–2436.

20. Mokone GG, Schwellnus MP, Noakes TD, Collins M. The COL5A1 gene and Achilles tendon pathology. Scand J Med Sci Sports. 2006;16(1):19–26.

21. September AV, Cook J, Handley CJ, van der Merwe L, Schwellnus MP, Collins M. Variants within the COL5A1 gene are associated with Achilles tendinopathy in two populations. Br J Sports Med. 2009;43(5):357–365.

22. September AV, Posthumus M, van der Merwe L, Schwellnus M, Noakes TD, Collins M. The COL5A1 and COL14A1 genes and Achilles tendon injuries. Int J Sports Med. 2008;29(3):257–263.

23. Bosmans T, Gasthuys F, Duchateau L, de Bruin T, Verhoeven G, Polis I. A comparison of tepoxalin-buprenorphine combination and buprenorphine for postoperative analgesia in dogs: a clinical study. J Vet Med A Physiol Pathol Clin Med. 2007;54(7):364–369.

24. Murray MM, Spindler KP, Ballard P, Welch TP, Zurakowski D, Nanney LB. Enhanced histologic repair in a central wound in the anterior cruciate ligament with a collagen-platelet-rich plasma scaffold. J Orthop Res. 2007;25(8):1007–1017.

25. Wang C, Ao Y, Wang J, Hu Y, Cui G, Yu J. Septic arthritis after arthroscopic anterior cruciate ligament reconstruction: a retrospective analysis of incidence, presentation, treatment, and cause. Arthroscopy. 2009;25(3):243–249.

Address correspondence to Chen Hong, MM, Sports Medicine and Joint Surgery, First People’s Hospital of Kunming, No. 1228 Beijing Road, Kunming, Yunnan Province 650000, China. Address e-mail to chenhong79@yandex.com.